Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect

Kidney International

Volumn 75, Issue 7, 2009, Pages 719-726

  Cook, Leslie G ^a   Chiasson, Valorie L ^b   Long, Cheng ^a   Wu, Gang Yi ^a   Mitchell, Brett M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Endothelium; Hypertension; Nitric oxide synthase; Protein kinase C

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; BLOCKING AGENT; CALCINEURIN AUTOINHIBITORY PEPTIDE; CALCINEURIN INHIBITOR; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FK 506 BINDING PROTEIN; NITRIC OXIDE SYNTHASE; PEPTIDE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RYANODINE RECEPTOR; SERINE; TACROLIMUS; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HYPERTENSION; INCUBATION TIME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; AORTA; CALCINEURIN; CALCIUM; ENDOTHELIAL CELLS; HYPERTENSION; MICE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE C; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 62349117691     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.697     Document Type: Article

References (33)

1. Morales JM, Dominguez-Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol 2006; 17: S296-S303.
2. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-222.
3. Mange KC, Cizman B, Joffe M et al. Arterial hypertension and renal allograft survival. J Am Med Assoc 2000; 283: 633-638.
4. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
5. Textor SC, Russell R, Wilson DJ et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-1339.
6. De Lima JJG, Xue H, Coburn L et al. Effects of FK506 in rat and human resistance arteries. Kidney Int 1999; 55: 1518-1527.
7. Takeda Y, Miyamori I, Furukawa K et al. Mechanisms of FK 506-induced hypertension in the rat. Hypertension 1999; 33: 130-136.
8. Long C, Cook LG, Wu GY et al. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007; 27: 1580-1586.
9. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001; 299: 818-824.
10. Ahern GP, Junankar PR, Dulhunty AF. Single channel activity of the ryanodine receptor calcium release channel is modulated by FK-506. FEBS Lett 1994; 352: 369-374.
11. Brillantes AB, Ondrias K, Scott A et al. Stabilization of calcium release channel (ryanodine receptor) function by FK-506 binding protein. Cell 1994; 77: 513-523.
12. Long C, Cook LG, Hamilton SL et al. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension 2007; 49: 569-576.
13. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807-818.
14. Sander M, Lyson T, Thomas GD et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1996; 9: 121S-138S.
15. Greif DM, Kou R, Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry 2002; 41: 15842-15853.
16. Harris MB, Ju H, Venema VJ et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276: 16587-16591.
17. Michell BJ, Chen ZP, Tiganis T et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001; 276: 17625-17628.
18. Gentile MT, Vecchione C, Maffei A et al. Mechanisms of soluble β-amyloid impairment of endothelial function. J Biol Chem 2004; 279: 48135-48142.
19. Martiny-Baron G, Kazanietz MG, Mischak H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976. J Biol Chem 1993; 268: 9194-9197.
20. Jiang XH, Yang F, Tan HM et al. Hyperhomocysteinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 2005; 25: 2515-2521.
21. Perrino BA. Regulation of calcineurin phosphatase activity by its autoinhibitory domain. Arch Biochem Biophys 1999; 372: 159-165.
22. Alvarez-Arroyo MV, Yague S, Wenger RM et al. Cyclophilin-mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular endothelial growth factor. Circ Res 2002; 91: 202-209.
23. Jin ZG, Lungu AO, Xie L et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 1186-1191.
24. Uittenbogaard A, Ying YS, Smart EJ. Characterization of a cytosilic heat-shock protein-caveolin chaperone complex: involvement in cholesterol trafficking. J Biol Chem 1998; 273: 6525-6532.
25. Yang H, Li M, Chai H et al. Effects of cyclophilin A on cell proliferation and gene expression in human vascular smooth muscle cells and endothelial cells. J Surg Res 2005; 123: 312-319.
26. Lungu AO, Jin ZG, Yamawaki H et al. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem 2004; 279: 48794-48800.
27. Bueno OF, Wilkins BJ, Tymitz KM et al. Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice. Proc Natl Acad Sci USA 2002; 99: 4586-4591.
28. Xin HB, Senbonmatsu T, Cheng DS et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 2002; 416: 334-337.
29. Ritter O, Schuh K, Brede M et al. AT2-receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J 2003; 17: 283-285.
30. Navarro-Antolin J, Hernandez-Perera O, Lopez-Ongil S et al. CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1. Kidney Int Suppl 1998; 68: S20-S24.
31. Navarro-Antolin J, Rey-Campos J, Lamas S. Transcriptional induction of endothelial nitric oxide gene by cyclosporine A: a role for activator protein-1. J Biol Chem 2000; 275: 3075-3080.
32. Kou R, Grief D, Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor: implications for the vascular responses to cyclosporin A. J Biol Chem 2002; 277: 29669-29673.
33. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.